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Abstract Endogenously generated or exogenously supplied 
nitric oxide causes cleavage of poly(ADP-ribose) polymerase 
(PARP) and apoptotic cell death in RAW 264.7 macrophages. 
With the use of NO donors such as S-nitrosoglutathione or 
spermine-NO we established that PARP digestion occurs in 
parallel with DNA fragmentation, and is preceded by accumula- 
tion of the tumor suppressor gene product p53. PARP cleavage in 
response to lipo~olysaccharide and interferon- 7 treatment is 
prevented by N"-monomethyl-L-arginine, thus proving a NO 
requirement. Endogenous NO generation, p53 accumulation, and 
PARP degradation occurred prior to the detection of significant 
chromatin condensation. In contrast, in stable Bcl-2 transfected 
cells, NO-initiated PARP cleavage was almost completely 
blocked. Our data implicate PARP as a proteolytic substrate 
during NO-mediated apoptotic cell death in RAW 264.7 
macrophages and establish Bcl-2 as an efficient signal terminator 
in this process. 
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1. Introduction 
Nitric oxide is endogenously produced by constitutive and 
inducible NO-synthase isoenzymes [1,2]. Biological actions of 
the molecule, classified by cGMP-dependent and cGMP-inde- 
pendent pathways, are attributed to physiology and patho- 
physiology. Recent evidence has established that endogen- 
ously generated or exogenously supplied NO is a potentially 
toxic compound. Toxicity of NO can often be described by 
morphological and biochemical features, characteristic of 
apoptosis. NO-induced apoptosis has been established for 
macrophages [3,4], I]-cells [5,6], chondrocytes [7], thymocytes 
[8], and several other systems. Accompanying apoptotic fea- 
tures one finds accumulation of the tumor suppressor gene 
product p53 as an early indicator of cell damage [9]. Although 
the apoptogenic action of NO is established, the NO species 
or the product of its redox chemistry as well as signaling 
mechanisms accounting for lethal reactions largely remain un- 
known. Recently, however, we have demonstrated that stable 
Bcl-2 gene transfer effectively suppressed the cell damaging 
activity of endogenously generated or exogenously supplied 
NO in RAW 264.7 macrophages, uggesting that the cell 
death pathway initiated by NO or its derivatives can be regu- 
lated by Bcl-2 family proteins. 
*Corresponding author. Fax: (49) (9131) 85 9202. 
Abbreviations: GSNO, S-nitrosoglutathione; LPS, lipopolysacchar- 
ide; IFN-y, interferon-T, Rbcl2-14, Bcl-2 transfected RAW 264.7 
macrophages clone 14; PARP, poly(ADP-ribose) polymerase. 
Despite the lack of knowledge about specific NO targets, 
some features of the death program appear highly conserved 
among experimental systems and different apoptogens. For 
example specific proteolytic events have been found to be 
involved in the process. In this regard interleukin-ll3 convert- 
ing enzyme (ICE protease) or other members of the group of 
proteolytic enzymes, related to the ced-3 gene product from 
Caenorhabditis elegans, become active during the early stages 
of apoptosis [10]. Apoptosis-related proteases, when activated, 
degrade proteins including histones [11], lamins [12], DNA 
topoisomerases [11], protein kinase C ~1, U1 small nuclear 
ribonucleoprotein [13], and poly(ADP-ribose) polymerase 
(PARP) [14,15]. Protease inhibitors of different specificities, 
including serine and cysteine protease inhibitors, have been 
shown to inhibit apoptosis which illustrates that apoptosis 
may require the activation of several classes of proteolytic 
enzymes [16]. An early biochemical event that accompanies 
apoptosis in many cell types is the proteolytic leavage of 
PARP from a 116 kDa polypeptide to a 31 kDa fragment 
containing the N-terminal DNA binding domain and a 85 
kDa polypeptide containing the automodification domain 
and the NAD" binding domain of the protein [14]. 
It is believed that DNA damage elicits a rapid stress re- 
sponse in mammalian cells, which involves attachment of 
PARP to the strand breaks and extensive synthesis of short- 
lived polymers by the bound enzyme. Although PARP has no 
direct role in DNA excision repair, the enzyme binds tightly 
to DNA breaks and sometimes interferes with repair if poly 
(ADP-ribose) synthesis is prevented [17]. However, with mas- 
sive PARP activation following extensive DNA damage, 
NAD +, the ADP-ribose donor, is depleted [18]. In an effort 
to resynthesize NAD--, ATP becomes depleted which ulti- 
mately leads to cell death due to energy deprivation. With 
regard to NO signaling, PARP activation followed by energy 
depletion has been associated with neurotoxicity [19] and NO- 
mediated islet cell death [20]. 
In our studies we became interested to define the role of 
PARP as a potential substrate of ICE-like proteases during 
NO-mediated apoptotic ell death. We show here that NO- 
induced apoptosis is accompanied by extensive PARP cleav- 
age, p53 accumulation, and apoptotic ell morphology. More- 
over, we provide evidence that Bcl-2 overexpression blocks 
PARP cleavage in response to NO in RAW 264.7 macro- 
phages. 
2. Materials and methods 
2.1. Materials 
Hoechst dye 33258, protein A sepharose, diphenylamine, and LPS 
(E. coli serotype 0127:B8) were purchased from Sigma (Deisenhofen, 
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Germany). [125I]Protein A (10 mCi/mg) was from DuPont New Eng- 
land Nuclear (Dreieich, Germany). The ECL detection reagents were 
ordered from Amersham (Braunschweig, Germany). Recombinant 
murine IFN-y was delivered by Boehringer Mannheim (Mannheim, 
Germany). The mouse monoclonal anti-PARP antibody (clone C-1I- 
10) was used with the kind permission of Guy Poirier, Department of 
Molecular Endocrinology, Centre Hospitalier de l'Universit6 Laval 
Research Center and Laval University (Quebec, Canada) provided 
by Dr. Alexander Btirkle, German Cancer Research Center (Heidel- 
berg, Germany). RPMI 1640 was ordered from Biochrom (Berlin, 
Germany). Cell culture supplements and fetal calf serum were from 
Gibco (Berlin, Germany). All other chemicals were of the highest 
grade of purity commercially available. 
2.2. Cell culture and cell treatment 
The mouse monocyte/macrophage cell line RAW 264.7 was main- 
tained in RPMI 1640 supplemented with 100 U/ml penicillin, 100 lag/ 
ml streptomycin, and 10% heat-inactivated fetal calf serum (complete 
RPMI). All experiments were performed using complete RPMI. For 
DNA fragmentation experiments, 4 x 106 cells were seeded into 6-well 
culture plates (106 cells/ml), allowed to adhere overnight, and incu- 
bated with the selected substances after the medium was changed. To 
investigate p53 expression, 2x 10 z cells were cultured and treated in 
the same way (10 cm Petri dishes, 20 ml/plate). Stimulation of endo- 
genous NO production was achieved with a combination of LPS (10 
lag/ml) and IFN- T (100 U/ml). 
2.3. Bcl-2 transfection 
For transfection 2 x 10 6 RAW 264.7 macrophages were seeded into 
a 10 cm Petri dish. After overnight adhesion, cells were transfected 
with 20 lag of the plasmid pRC/CMVbcl2 encoding the full-length 
human bcl-2 gene under the CMV promoter by using the calcium 
phosphate precipitation method [21]. Transfected single clones were 
picked randomly after selection with 400 lag/ml geneticin. Stable Bcl-2 
protein expression was assessed by Western blot analysis with an anti- 
human Bcl-2 specific antibody (clone 124, DAKO, Hamburg, Ger- 
many). One clone termed Rbcl2-14 showed the highest level of the 
Bcl-2 protein. Alternatively, RAW cells were transfected with a con- 
trol plasmid lacking the bcl-2 gene (termed Rneo-2). 
2.4. GSNO synthesis 
GSNO (S-nitroso derivative of glutathione) was synthesized, char- 
acterized, and used as described previously [9]. 
2.5. Quantitation of DNA fragmentation 
DNA fragmentation was essentially assayed as reported previously 
[3]. Briefly, after incubation cells were scraped off the culture plates, 
resuspended in 250 ~tl 10 mM Tris, 1 mM EDTA, pH 8.0 (TE buffer), 
and incubated with an additional volume lysis buffer (5 mM Tris, 20 
mM EDTA, pH 8.0, 0.5% Triton X-100) for 30 min at 4°C. After 
lysis, the intact chromatin (pellet) was separated from DNA fragments 
(supernatant) by centrifugation for 15 min at 13 000xg. Pellets were 
resuspended in 500 ~tl TE buffer and samples were precipitated by 
adding 500 ~tl 10% trichloroacetic acid at 4°C. Samples were pelleted 
at 4000 rpm for 10 min and the supernatant was removed. After 
addition of 300 lal 5% trichloroacetic acid, samples were boiled for 
15 min. DNA contents were quantitated using the diphenylamine 
reagent [22]. The percentage of DNA fragmented was calculated as 
the ratio of the DNA content in the supernatant to the amount in the 
pellet. 
2.6. Quantitation of apoptotic ells 
Macrophages (4X 10 ~) were grown in 12-well plates. After adhe- 
sion, cells were stimulated, followed by fixation onto glass slides 
with 3% paraformaldehyde for 5 min. Samples were washed with 
phosphate-buffered saline, stained with Hoechst dye H33258 (8 lag/ 
nal) for 5 min, washed with distilled water, and mounted in Kaiser's 
glycerol gelatin. Nuclei were visualized using a Leitz fluorescence mi- 
croscope. In each sample a minimum of 500 cells were counted and 
apoptotic nuclei were expressed as percent of total nuclei. 
2.7. Nitrite determination 
Nitrite, a stable NO oxidation product, was determined using the 
Griess reaction [23] following a standard procedure [9]. 
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2.8. p53 quantification 
p53 was quantified by immunoprecipitation f llowed by Western 
blot analysis as described previously [9]. Briefly, cells were scraped 
off and lysed in 700 lal lysis buffer (50 mM Tris, 5 mM EDTA, 150 
mM NaC1, 0.5% Nonidet-40, 1mM PMSF, pH 8.0). Lysed cells were 
sonicated with a Branson sonifier (10 s, duty cycle 100%, output 
control 1). After centrifugation non-specific adsorbents were removed 
from the resulting supernatant with 40 lal 50% (v/v) protein A-sephar- 
ose. p53 was immunoprecipitated by adding 200 lal hybridoma super- 
natant (clone PAb 122, kindly provided by Hans Stahl, Universitfit 
des Saarlandes, Homburg, Germany) and 50 lal 50% protein A-se- 
pharose. Immune complexes were washed 3 times with 500 lal SNNTE 
(5% sucrose, 1% Nonidet-40, 0.5 M NaC1, 50 mM Tris, 5 mM EDTA, 
pH 7.4) and once more with 1 ml SNNTE. Finally, samples were 
resuspended in sample buffer, resolved on SDS-polyacrylamide g ls, 
and blotted onto nitrocellulose sheets. Sheets were washed twice with 
TBS (140 mM NaCI, 50 mM Tris, pH 7.2) containing 0.1% Tween-20 
before blocking non-specific binding with TBS/2% BSA. The p53 anti- 
body was added (hybridoma supernatant against p53; clone PAb122; 
1:6 in TBS/0.2% BSA) and incubated overnight at 4°C. Nitrocellulose 
sheets were washed 5 times and non-specific binding was blocked as 
described. For detection, blots were incubated with [12SI]protein A (2 
ng/ml protein A, 1 laCi in TBS/0.06% Tween-20/0.1% BSA) for 2 h 
followed by quantitative determination of radioactivity using the 
phosphor image system (Molecular Dynamics) [24]. 
2.9. PARP Western blot analysis 
Cell lysis was achieved with lysis buffer (50 mM Tris, 5 mM EDTA, 
150 mM NaC1, 0.5% Nonidet-40, 1 mM PMSF, pH 8.0) and sonica- 
tion (Branson sonifier; 10 s, duty cycle 100%, output control 40%), 
followed by centrifugation (4000xg, 5 min), and Bradford protein 
determination [25]. Proteins were normalized to 100/.tg/lane, resolved 
on 7.5% polyacrylamide gels and blotted onto nitrocellulose sheets 
basically following the method as described for p53. Filters were in- 
cubated with the mouse anti-PARP antibody (clone C-II-10, hybrido- 
ma supernatant, 1:5 in TBS+0.5%o milk powder) overnight at 4°C. 
Detection was by horseradish peroxidase-conjugated goat anti-mouse 
monoclonal ntibodies (1:5000) for 1 h at room temperature using the 
ECL method (Amersham). 
2.10. Statistical analyses 
Each experiment was performed at least three times and statistical 
analysis were performed using the two tailed Student's t-test. 
3. Results and discussion 
We have recently studied the characteristics of NO- 
mediated cell death in several cellular systems including mouse 
macrophages [3,9]. In this respect he RAW 264.7 cell system 
serves as a model system in analogy to mouse peritoneal 
macrophages [4]. NO-initiated signaling pathways may be, 
at least in part, extrapolated to other systems like [3-cells [9] 
or thymocytes [26]. Generally, exogenous NO donor applica- 
tion or induction of the NO synthase followed by concomitant 
NO generation resulted in cell death by apoptosis. RAW 
264.7 macrophages respond to S-nitrosoglutathione or sper- 
mine-NO with a time-dependent increase in p53 protein accu- 
mulation and DNA fragmentation, quantitated with the di- 
phenylamine assay (Fig. 1A). Following the addition of NO 
donors, p53 accumulation clearly preceded DNA fragmenta- 
tion by several hours. Probing for PARP cleavage in macro- 
phage cell extracts employing Western blotting revealed pro- 
teolytic digestion of the 116 kDa holoenzyme into the 85 kDa 
subunit in response to exogenously supplied NO (Fig. 1B). 
PARP cleavage was more pronounced with spermine-NO 
which is in line with a slightly enhanced p53 response and 
apoptotic DNA fragmentation of raw cells treated with sper- 
mine-NO compared to GSNO. The 85 kDa PARP protein, 
which is indicative of proteolytic holoenzyme digestion, is 
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Fig. 1. PARP cleavage, p53 accumulation, and DNA fragmentation 
in response to NO-releasing compounds. (A) RAW 264.7 macro- 
phages were exposed to 1 mM GSNO or 250 txM spermine-NO for 
the times indicated, p53 was immunoprecipitated and analyzed by 
Western blotting as outlined in section 2. The data are representa- 
tive of three independent experiments. DNA fragmentation was 
quantitated with the diphenylamine assay (mean values__ standard 
deviation, n-> 3). (B) Cells (5×10 ~) were incubated with 1 mM 
GSNO or 250 txM spermine-NO for various times. Controls (C) 
were left untreated for 8 h. PARP (116 kDa holoenzyme or 85 kDa 
fragment) was analyzed by Western blotting using the monoclonal 
anti-PARP antibody C-II-10, followed by ECL detection. Blots are 
representative of three similar experiments. 
visible after a 3~-h  incubation period with spermine-NO and 
a 4-5-h exposure period to GSNO. For both NO-releasing 
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compounds PARP digestion coincided with DNA fragmenta- 
tion rather than p53 accumulation. 
RAW macrophages, timulated with LPS and IFN- 7 as 
agonists, express high levels of the inducible form of NO- 
synthase as determined by nitrite accumulation in the cell 
supernatant (Fig. 2). Nitrite generation is significant after a 
lag period of 9 h and showed a plateau phase after 20-24 h 
following agonist addition. LPS/IFN-7-induced nitrite produc- 
tion was drastically repressed in the presence of the NO- 
synthase inhibitor NG-monomethyl-L-arginine (NMMA) 
(Fig. 2A), applied together with agonists at a concentration 
of 1 mM. Probing for p53 levels in control macrophages re- 
vealed hardly detectable l vels of the tumor suppressor (Fig. 
2B). Addition of LPS/IFN-7 caused visible p53 accumulation 
after 12-15 h with a peak of protein detection around 22 h. 
The NO-synthase inhibitor NMMA completely suppressed 
the p53 response. In LPS/IFN-7-exposed macrophages, death 
occurred by apoptosis as judged by morphological param- 
eters, i.e. chromatin condensation (Fig. 2C). Again cellular 
apoptosis is prevented by NMMA addition. Furthermore, 
we tested the involvement of endogenously produced NO in 
PARP cleavage (Fig. 2D). At 15 h post LPS/IFN- 7 addition 
PARP was partially cleaved as demonstrated by detection of 
the 85 kDa protein fragment. In contrast, PARP cleavage was 
suppressed in NMMA-treated cells, thus substantiating the 
action of endogenously generated NO for PARP digestion 
in LPS/IFN-7-treated cells. These data therefore show that 
analogous to exogenously supplied NO donors, endogenous 
NO formation caused PARP cleavage which became detect- 
able in parallel with the onset of DNA fragmentation or the 
appearance of characteristic apoptotic ell morphology. 
Taken together, these observations suggest a link between 
NO-mediated apoptotic signaling and an increase in the cel- 
lular ICE or ICE-like protease activities which ultimately re- 
sult in the proteolytic leavage of PARP. In the nematode C. 
elegans programmed cell death is dependent on ced-3, an ICE- 
like cysteine protease, and suppressed by ced-9, a homolog of 
the anti-apoptotic mammalian protein Bcl-2 [27]. We there- 
fore focused our investigations around Bcl-2. Stable transfec- 
tion of Bcl-2 provided macrophages with protection against 
NO intoxication and apoptotic ell death. To assay the role of 
Bcl-2 in terms of PARP cleavage, we incubated control-trans- 
fected (Rneo-2) and bcl-2 transfected (Rbcl2-14) RAW 264.7 
macrophages with GSNO, and then determined the relative 
levels of the 116 kDa versus the 85 kDa form of the PARP 
protein. After 4 and 8 h, respectively, PARP becomes de- 
graded in parent and neomycin-control-transfected RAW 
264.7 cells (Fig. 3). In contrast, Bcl-2 gene transfer completely 
abrogated NO-initiated PARP cleavage. In addition to inhibi- 
tion of PARP proteolysis, Bcl-2 also prevented NO-mediated 
induction of apoptosis in transformed RAW 264.7 macro- 
phages (Mel3mer, Reed, and Brtine, manuscript submitted). 
Our data on NO-mediated PARP cleavage xtend previous 
reports demonstrating proteolytic digestion of PARP induced 
by agonists uch as TNF-cx and Fas [28]. PARP cleavage to a 
85 kDa fragment is an early event in apoptosis and is ob- 
served in virtually every form of programmed cell death. Pro- 
teolysis results in separation of its DNA binding versus poly 
(ADP-ribose) polymerase activities. The endonuclease impli- 
cated in apoptotic DNA cleavage is negatively regulated by 
poly-ADP-ribosylation. Therefore, PARP cleavage could re- 
sult in endonuclease activation in DNA-damaged cells. Our 
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observations suggest an increase in the intracellular ICE-like 
protease activities either by elevated expression or by activa- 
tion as a result of NO-signaling. Although it has been difficult 
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Fig. 2. Endogenous NO production induces PARP cleavage, p53 ac- 
cumulation, and apoptotic ell death in RAW 264.7 macrophages. 
(A, C) Macrophages (4x 105) were seeded into 12-well culture plates 
and stimulated for various times with vehicle (filled squares), 10 pg/ 
ml LPS and 100 units/ml IFN-T (filled circles), or 10 ktg/ml LPS, 
100 units/ml IFN-y and 1 mM NMMA (open circles). Nitrite was 
determined with the Griess reaction. Apoptotic ells exhibiting char- 
acteristic hromatin condensation were counted by fluorescence mi- 
croscopy. Values represent means + standard eviation of four inde- 
pendent experiments. (B) Cells (2 x 107) were stimulated as outlined 
in (A) and p53 protein was determined as described in Fig. 1. (D) 
Cells (5X 106) were exposed to 10 I.tg/ml LPS and 100 units/ml IFN- 
7 (L + I), 10 pg/ml LPS, 100 units/ml IFN-y and 1 mM NMMA 
(L + I + N), or remained as controls (C) for the times indicated. 
PARP cleavage was monitored by Western blot analysis. For other 
details ee Fig. 1B. 
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Fig. 3. Bcl-2 blocks PARP cleavage in response to NO donor expo- 
sure. RAW 264.7 macrophages (5x 106), a neomycin-vector control 
clone (Rneo-2), and a Bcl-2 transfectant clone (Rbcl2-14) were incu- 
bated for 4 or 8 h with vehicle (control) or 1 mM GSNO as indi- 
cated. Proteins were normalized to 100 p.g/lane and PARP protein 
(116 kDa holoenzyme and 85 kDa fragment) was examined by Wes- 
tern blotting. Details are as in Fig. lB. 
to define exactly the pathophysiological role(s) of PARP, the 
enzyme appears to be associated with DNA damage-evoked 
stress responses, as well as with apoptosis [29]. In special 
cases, such as NO-induced neurotoxicity [19] or pancreatic 
islet cell lysis [20], massive activation of PARP, and subse- 
quent NAD + depletion followed by ATP deprivation may 
represent a major cause of cell death. Protection against cell 
killing by the rather non-specific PARP inhibitor 3-aminoben- 
zamide [30] has provided some supportive vidence. In con- 
trast, in most other systems, PARP inhibitors ensitize cells to 
DNA damage [31]. Thus PARP activation and toxicity is not 
directly correlative [32]. In RAW 264.7 macrophages, NO- 
mediated apoptosis neither evokes NAD + depletion nor re- 
suits in ATP deprivation [33]. Moreover, PARP inhibitors are 
non-protective. In macrophages the death pathway character- 
ized as apoptotic seems to involve PARP cleavage rather than 
causing its activation. This seems consistent with the idea that 
apoptosis initiated by NO is an energy requiring process. 
Although PARP cleavage may be a concomitant of apoptosis, 
cleaved and inactivated PARP is probably not the cause of 
apoptosis in this circumstance. Generally, we like to conclude 
that NO-induced apoptosis activates a common proteolytic 
pathway that induced PARP digestion in analogy to agonists 
like TNF-tx or Fas. The process of apoptotic PARP cleavage 
has to be discriminated from death signals which cause PARP 
activation and NAD + depletion. 
Considering that PARP cleavage inhibits most of its DNA 
repair activity [14], we assume that NO-mediated activation of 
ICE or related proteases may contribute to the demise of the 
cell. It has been proposed that proteases of the ICE enzyme 
family are involved in initiating the active phase of apoptosis 
with inhibition of activated proteases abolishing all manifes- 
tations of apoptosis [34]. For NO-mediated apoptosis, PARP 
cleavage occurs in parallel with the relatively late phase char- 
acterized by DNA fragmentation. In contrast, accumulation 
of p53 appears to be a much earlier marker for the apopto- 
genic signaling of NO. 
NO-initiated apoptosis is effectively blocked by Bcl-2 trans- 
fection. Bcl-2 transfection into macrophages also provided 
protection against NO-evoked DNA fragmentation, although 
leaving NO-mediated p53 accumulation unaltered (Mel3mer, 
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Reed and Briine, manuscript submitted). Here we demon- 
strate that Bcl-2 transfection blocks NO-induced PARP 
breakdown. It must be concluded that Bcl-2 blocks apoptotic 
signaling at a step distal to the p53 response and proximal to 
PARP cleavage or activation of the ICE-related proteases. 
Our results encompass the involvement of an ICE-like pro- 
tease in PARP proteolysis during NO-mediated apoptotic ell 
death in RAW 264.7 macrophages. In the RAW cell line, and 
presumably as a general mechanism apoptotic signaling in- 
itiated by NO promotes PARP breakdown in parallel with 
DNA cleavage. NO-initiated signal transducing mechanisms 
resulting in proteolytic digestion of proteins uch as PARP are 
efficiently antagonized by the anti-apoptotic protein Bcl-2. 
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